-
Pyrazoline B Induces Oxidative Stress Mediated Toxicity, Cell Cycle Arrest, and Caspase-Independent Apoptosis in BT-474 Human Breast Cancer Cells
13 Dec 2025 10:08 GMT
… rates to paclitaxel treatment have been widely … to evaluate the pharmacokinetics, drug-likeness, and medicinal … , renal cell carcinoma, gastrointestinal stromal tumor, differentiated thyroid carcinoma, … means of treating cancer.74 Therefore, drugs that …
-
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
09 Dec 2025 00:45 GMT
… a novel drug developed by Ascentage Pharma and represents the … dehydrogenase (SDH)-deficient gastrointestinal stromal tumors. Notably, the POLARIS-1 … an FDA-cleared, global registrational Phase III trial, … inhibitor for the treatment of various hematologic …
-
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
09 Dec 2025 00:45 GMT
… (SDH)- deficient gastrointestinal stromal tumors (GIST). Ascentage Pharma has signed an exclusive … , some patients develop drug resistance or intolerance during treatment with TKIs. Prior … conducting an FDA-cleared, global registrational Phase III trial, or …
-
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
09 Dec 2025 00:45 GMT
… a novel drug developed by Ascentage Pharma and represents … (SDH)-deficient gastrointestinal stromal tumors (GIST). Ascentage Pharma has signed an … long-term treatment, reinforcing the drug’s established … an FDA-cleared, global registrational Phase III trial, …
-
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
08 Dec 2025 12:30 GMT
… .S. Food and Drug Administration (FDA) for bezuclastinib in … will become an important treatment option for this patient … company focused on developing precision therapies for … in patients with advanced gastrointestinal stromal tumors (GIST), a type …
-
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy
25 Nov 2025 00:00 GMT
… novel drug, olverembatinib (HQP1351), in patients with gastrointestinal stromal tumors ( … clinically available to treat SDH-deficient GISTs. … development program to bring a safe and effective new treatment … FDA in the US. About Ascentage Pharma Ascentage Pharma …
-
<![CDATA[Gastrointestinal Stromal Tumor: Comprehensive Patient Guide]]>
17 Oct 2025 00:55 GMT
… Are Gastrointestinal Stromal Tumors (GISTs)?
Gastrointestinal stromal tumors, or … essential for developing an effective treatment plan. … guide treatment selection and clinical trial eligibility. … adjustments, supportive medications, or lifestyle strategies …
-
<![CDATA[FDA Grants Fast Track Status to New Gastric Cancer Treatment]]>
19 Nov 2025 22:07 GMT
… Food and Drug Administration (FDA) has granted … develops and responds to treatment.
“We are honored that the FDA … Drugs that modulate condensates may offer new ways to treat … neuroendocrine tumors, gastrointestinal stromal tumors and primary gastric …
-
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress
16 Nov 2025 16:26 GMT
… new drug application with the Food and Drug Administration for its treatment candidate … phase 3 trial showed promising developments. During the study, patients with Gastrointestinal Stromal Tumors (GIST …
-
<![CDATA[Bezuclastinib Plus Sunitinib Achieves Strong PFS Benefit in Phase III PEAK Trial for Imatinib-Resistant GIST]]>
11 Nov 2025 01:50 GMT
… conclusive.
Estimated mean duration of treatment with the bezuclastinib combination is … submit a New Drug Application (NDA) to the FDA for bezuclastinib in … from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST). News release. Cogent …
About
© 1995-2025